financetom
Business
financetom
/
Business
/
SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge
Mar 25, 2026 6:36 AM

NORTH PALM BEACH, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. ( SRXH ) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced hedging its decentralized finance (DeFi) portfolio with investment in Gold. The Company has also reduced its hedge on emerging markets.

Michael Young, Director of SRx Health, commented, "We are looking forward to the closing of EMJX in the near future."

Additional Information and Where to Find It

In connection with the proposed transaction between the Company and EMJX intends to file with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement will include an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENTAND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus, as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available, at the SEC's website at www.sec.gov. The information on EMJX's or the Company's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company Contact

SRx Health Solutions, Inc. ( SRXH )

Kent Cunningham, Chief Executive Officer

Investor Relations Contact

KCSA Strategic Communications

Valter Pinto, Managing Director

212-896-1254

[email protected]

Image: https://www.globenewswire.com/newsroom/ti?nf=OTY3ODMzOCM3NTAzMDI3IzIwOTg4MjA=

Image: https://ml.globenewswire.com/media/YThhOTYxNWEtZmMxOC00NmZiLWJlNTgtZGQwODQxNjA4ZDczLTExMTAzOTEtMjAyNi0wMy0yNS1lbg==/tiny/SRx-Health-Solutions-Inc-.png Image: Primary Logo

Source: SRx Health Solutions, Inc. ( SRXH )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
AbbVie cuts 2025 profit forecast on acquisition expenses
AbbVie cuts 2025 profit forecast on acquisition expenses
Apr 3, 2025
(Reuters) -AbbVie ( ABBV ) on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and development costs. The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection in 2023. To that end, the company...
BRIEF-Sonim Technologies Special Committee Confirms Receipt Of Unsolicited Proposal For $4.00 Per Share In Cash
BRIEF-Sonim Technologies Special Committee Confirms Receipt Of Unsolicited Proposal For $4.00 Per Share In Cash
Apr 3, 2025
April 3 (Reuters) - Sonim Technologies Inc ( SONM ): * SONIM TECHNOLOGIES, INC. ( SONM ) SPECIAL COMMITTEE CONFIRMS RECEIPT OF UNSOLICITED PROPOSAL FOR $4.00 PER SHARE IN CASH * SONIM TECHNOLOGIES:RECEIVED UNSOLICITED NON-BINDING PROPOSAL FROM ORBIC NORTH AMERICA TO ACQUIRE ALL SHARES OF CO FOR $4.00 PER SHARE IN CASH * SONIM TECHNOLOGIES ( SONM ): SPECIAL COMMITTEE...
BRIEF-Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics
BRIEF-Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics
Apr 3, 2025
April 3 (Reuters) - CASI Pharmaceuticals Inc ( CASI ): * CASI PHARMACEUTICALS INC ( CASI ): SIGNS AGREEMENT TO ACQUIRE EQUITY INTERESTS IN PRECISION AUTOIMMUNE THERAPEUTICS * CASI PHARMACEUTICALS ( CASI ): TO ACQUIRE ALL OF EQUITY INTEREST IN PRECISION AUTOIMMUNE THERAPEUTICS AT RMB28.4 MILLION Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved